March 19, 2020 / 11:18 AM / 15 days ago

BRIEF-Hansoh Pharma's Ameile Receives Marketing Authorization In China For Second-Line Treatment For Patients With Type Of Non-Small Cell Lung Cancer

March 19 (Reuters) - Hansoh Pharmaceutical Group Co Ltd :

* HANSOH PHARMA’S AMEILE (ALMONERTINIB) RECEIVES MARKETING AUTHORIZATION IN CHINA FOR SECOND-LINE TREATMENT FOR PATIENTS WITH EGFR T790M-MUTATION NON-SMALL CELL LUNG CANCER Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below